Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + orelabrutinib
- Development stage
- Unknown
- Lead developer
- Affiliated Hospital of Nantong University
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
The PRO regimen is a chemotherapy-free combination therapy consisting of polatuzumab vedotin, rituximab, and orelabrutinib. Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate (ADC) that delivers the microtubule inhibitor monomethyl auristatin E (MMAE) to B cells. Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on the surface of B-lymphocytes, leading to cell death through various immune-mediated mechanisms. Orelabrutinib is a highly selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK), which plays a crucial role in B-cell receptor signaling. This combination is currently being evaluated in a Phase 2 clinical trial led by the Affiliated Hospital of Nantong University for the treatment of elderly, frail, treatment-naive patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
- Other names
- Polatuzumab vedotin, Rituximab, and Orelabrutinib combination
02
Targets
TUBB (Tubulin (alpha and beta subunits))B-cell antigen receptor complex-associated protein beta chainBTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + orelabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + orelabrutinib.